Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is the undisputed pioneer in the underpenetrated $100B MCED market and is actively building a self-pay market and laying the groundwork for broad institutional adoption. Their Q1 beat with 56,000 Galleri tests and $40.8M in revenue indicates strong demand for their breakthrough multi-cancer early detection blood test, and their guidance conservatism reflects uncertainty rather than lack of potential. With upcoming catalysts including ASCO data drop and FDA approval, and a favorable risk/reward profile, GRAIL is a strong buy in the MCED market.

Bears say

GRAIL is facing significant pressures on its top line, with a decline in average selling prices and increased volume discounts leading to a marginal beat on Q1 revenues. Despite impressive growth in the number of prescribers in the first quarter, the company's wide range outlook for the rest of the year points to uncertainty in FDA approval and potential challenges in securing Medicare reimbursement. Additionally, the extensive and complex process of gathering data for its cancer detection technology may pose operational risks and impact the company's ability to meet expectations.

GRAIL Inc (GRAL) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 7 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.